Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_federal_law
|
| gptkbp:administeredBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:amendedBy |
gptkb:21st_Century_Cures_Act
|
| gptkbp:appliesTo |
Medical devices
Biologics Drugs |
| gptkbp:codifiedIn |
gptkb:United_States_Code
|
| gptkbp:dateEnacted |
2004
|
| gptkbp:enactedBy |
gptkb:United_States_Congress
|
| https://www.w3.org/2000/01/rdf-schema#label |
21 U.S.C. § 360bbb-3
|
| gptkbp:legalCitation |
gptkb:21_U.S.C._§_360bbb-3
|
| gptkbp:partOf |
gptkb:21_U.S.C._Chapter_9
|
| gptkbp:permits |
FDA to issue Emergency Use Authorizations
|
| gptkbp:providesFor |
Authorization for medical products for use in emergencies
|
| gptkbp:subject |
gptkb:Emergency_Use_Authorization
|
| gptkbp:usedDuring |
gptkb:COVID-19_pandemic
|
| gptkbp:bfsParent |
gptkb:Section_564_of_the_Federal_Food,_Drug,_and_Cosmetic_Act
|
| gptkbp:bfsLayer |
6
|